IKENA ONCOLOGY INC. news, videos and press releases
For more news please use our advanced search feature.
IKENA ONCOLOGY INC. - More news...
IKENA ONCOLOGY INC. - More news...
- Ikena Oncology Reports Third Quarter 2024 Financial Results
- Ikena Oncology Reports Second Quarter 2024 Financial Results
- UPDATE – Ikena Oncology Announces Strategic Update
- Ikena Oncology Announces Strategic Update
- Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
- Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
- Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
- Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
- Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
- Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
- Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
- Ikena Oncology to Present at Multiple November 2023 Investor Conferences
- Ikena Oncology to Participate in September 2023 Investor Conferences
- Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
- Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
- Ikena Oncology to Participate in Upcoming Investor Conferences
- Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
- Ikena Oncology Announces $40 Million Underwritten Offering
- Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
- Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
- Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
- Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
- Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
- Ikena Oncology Appoints Owen Hughes as Board Chair
- Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
- Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
- UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
- Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
